



Celldex Therapeutics, Inc.  
Investor Relations Department  
119 Fourth Avenue  
Needham, MA 02494-2725  
United States

[Visit IR website](#)   
[Sign-up for email alerts](#)

|                                  |                            |
|----------------------------------|----------------------------|
| <b>NASDAQ: CLDX</b> <sup>1</sup> |                            |
| Last Trade:                      | 0.69                       |
| Trade Time:                      | 4:00 PM ET<br>Apr 23, 2018 |
| Change:                          | -0.01  (1.843%)            |
| Day Range                        | 0.66 - 0.71                |
| 52-Week Range                    | 0.65 - 3.42                |
| Volume                           | 4,246,128                  |
| Market Cap. (\$M)                | 96.915                     |
| Shares Out (M)                   | 141.070                    |

<sup>1</sup> The stock information is provided by eSignal, stock charts are provided by EDGAR Online. Stock information is delayed approximately 20 minutes.

## Company Profile

Celldex Therapeutics, Inc. is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response.

... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

- Apr 20, 2018*  
[Data from Multiple Celldex Programs Presented at American Association for Cancer Research \(AACR\) Annual Meeting 2018](#)
- Apr 16, 2018*  
[Celldex's METRIC Study in Metastatic Triple-negative Breast Cancer Does Not Meet Primary Endpoint](#)
- Mar 7, 2018*  
[Celldex Provides Corporate Update and Reports Full Year 2017 Results](#)
- Mar 2, 2018*  
[Celldex to Report Fourth Quarter and Year-End 2017 Business/Financial Results and Present at Upcoming Investor Conference](#)
- Nov 30, 2017*  
[Celldex Therapeutics Initiates Phase 1 Study of New Product Candidate CDX-1140 in Solid Tumors](#)

## Events [\[ View all \]](#)

There are no events to display at this time. Please check back later.

## Financials [\[ View all \]](#)

### [Fourth Quarter Financial Results](#)

- Mar 7, 2018*  
[Annual Report \(10-K\)](#)
- Apr 28, 2017*  
[Definitive Proxy Statement](#)
- Nov 7, 2017*  
[Quarterly Report \(10-Q\)](#)
- Aug 8, 2017*  
[Quarterly Report \(10-Q\)](#)
- May 9, 2017*  
[Quarterly Report \(10-Q\)](#)